羟乙基淀粉预防卵巢过度刺激综合征的应用进展
摘要
卵巢过度刺激综合征(OHSS)是一种主要发生在辅助生殖技术促排卵时的自限性疾病,没有特异性疗法。近年来国内外有大量文献报道羟乙基淀粉溶液能够起到显著预防OHSS的作用。本文就近年羟乙基淀粉溶液预防OHSS的应用进展进行分析总结,基于目前对羟乙基淀粉溶液的研究,发现其对预防OHSS的效果是明确的,可以降低OHSS发生率及严重程度,且妊娠期使用对胎儿也是安全的。然而羟乙基淀粉溶液预防OHSS的使用尚缺乏适应证,所以在大量使用于临床前,仍需要质量高的随机对照研究来证实。
引文
[1]GOMEZ R,SOARES S R,BUSSO C,et al.Physiology and pathology of ovarian hyperstimulation syndrome[J].Semin Reprod Med,2010,28(6):448-457.
[2]ORVIETO R,DRATVIMAN-STOROBINSKY O,COHEN Y.Interleukin-2 production by cultured human granulosa cells[J].Am J Reprod Immunol,2015,74(5):392-397.
[3]CHEN S U,CHOU C H,LIN C W,et al.Signal mechanisms of vascular endothelial growth factor and interleukin-8in ovarian hyperstimulation syndrome:dopamine targets their common pathways[J].Hum Reprod,2010,25(3):757-767.
[4]ABRAMOV Y,NAPARSTEK Y,ELCHALAL U,et al.Plasma immunoglobulins in patients with severe ovarian hyperstimulation syndrome[J].Fertil Steril,1999,71(1):102-105.
[5]DELVIGNE A,ROZENBERG S.Review of clinical course and treatment of ovarian hyperstimulation syndrome(OHSS)[J].Hum Reprod Update,2003,9(1):77-96.
[6]LEVIN I,GAMZU R,HASSON Y,et al.Increased erythrocyte aggregation in ovarian hyperstimulation syndrome:apossible contributing factor in the pathophysiology of this disease[J].Hum Reprod,2004,19(5):1076-1080.
[7]郭莉,张晓霞.羟乙基淀粉溶液对卵巢过度刺激综合征的预防作用[J].吉林大学学报(医学版),2016,42(6):1147-1150.
[8]倪亚莉,柴三明.羟乙基淀粉溶液预防卵巢过度刺激综合征的系统评价[J].实用妇产科杂志,2013,29(7):539-542.
[9]RIZK B.Symposium:Update on prediction and management of OHSS.Genetics of ovarian hyperstimulation syndrome[J].Reprod Biomed Online,2009,19(1):14-27.
[10]YOUSSEF M,AL-INANY H G,EVERS J L,et al.Intravenous fluids for the prevention of severe ovarian hyperstimulation syndrome[J].Cochrane Database Syst Rev,2011(2):CD001302.
[11]王佩玉,赵军招.中药和万汶在预防卵巢过度刺激综合征中的临床应用比较[J].温州医科大学学报,2017,47(2):104-109.
[12]KONIG E,BUSSEN S,SUTTERLIN M,et al.Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients:aprospective,randomized,double-blind and placebo-controlled study[J].Hum Reprod,1998,13(9):2421-2424.
[13]MATORRAS R,ANDRES M,MENDOZA R,et al.Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients:randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch[J].Eur J Obstet Gynecol Reprod Biol,2013,170(2):439-443.
[14]ABRAMOV Y,FATUM M,ABRAHAMOV D,et al.Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome:apreliminary report[J].Fertil Steril,2001,75(6):1228-1230.
[15]KIESEWETTER H,BLUME J,JUNG F,et al.Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb[J].J Intern Med,1990,227(2):107-114.
[16]YOUSSEF M A,MOURAD S.Volume expanders for the prevention of ovarian hyperstimulation syndrome[J].Coch Datab Syst Rev,2016(8):CD001302.
[17]GUO J L,ZHANG D D,ZHAO Y,et al.Pharmacologic interventions in preventing ovarian hyperstimulation syndrome:a systematic review and network meta-analysis[J].Sci Rep,2016,6:19093.
[18]MOURAD S,BROWN J,FARQUHAR C.Interventions for the prevention of OHSS in ART cycles:an overview of Cochrane reviews[J].Coch Datab Syst Rev,2017,1:CD012103.
[19]EL-KHAYAT W,ELSADEK M.Calcium infusion for the prevention of ovarian hyperstimulation syndrome:a double-blind randomized controlled trial[J].Fertil Steril,2015,103(1):101-105.
[20]NAREDI N,TALWAR P,SANDEEP K.VEGF antagonistforthepreventionofovarianhyperstimulation syndrome:Current status[J].Med J Armed Forces India,2014,70(1):58-63.
[21]JEE B C,SUH C S,KIM Y B,et al.Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome:a systematic review and meta-analysis[J].Gynecol Obstet Invest,2010,70(1):47-54.
[22]王兰,赵义清.卵巢过度刺激综合征临床相关研究进展[J].发育医学电子杂志,2015,3(2):116-120.
[23]TANG H,MOURAD S,ZHAI S D,et al.Dopamine agonists for preventing ovarian hyperstimulation syndrome[J].Coch Datab Syst Rev,2016,11:CD008605.
[24]JEE B C,SUH C S.Administration of intravenous albumin around the time of oocyte retrieval reduces preenancy rate without preventing ovarian hyper stimulation syndrome:a systematic review and meta-analysis[J].Gynecol Obstet Invest,2010,70(1):47-54.
[25]VENETIS C A,KOLIBIANAKIS E M.Intavenous albumin administration for the prevention of sever ovarian hyper stimulation syndrome:A systematic review and metaanalysis[J].Fertile Sterile,2011,95(1):162-164.
[26]赵玲玲,樊丽莎.多囊卵巢综合征的诊断学现状[J].中国实验诊断学,2015,19(1):162-164.
[27]LAXENAIRE M C,CHARPENTIER C,FELDMAN L.Anaphylactoid reactions to colloid plasma substitutes:incidence,risk factors,mechanisms.A French multicenter prospective study[J].Ann Fr Anesth Reanim,1994,13(3):301-310.
[28]BELLOMO R,BION J,FNFER S,et al.Open letter to the Executive Director of the European Medicines Agency concerning the licensing of hydroxyethyl starch solutions for fluid resuscitation[J].Br J Anaesth,2014,112(3):595-600.
[29]MARGRAF A,HERTER J M,KUEHNE K,et al.6%Hydroxyethyl starch(HES 130/0.4)diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice[J].Crit Care,2018,22(1):111.
[30]OH H W,LEE J H,KIM J T.Safety of hydroxyethyl starch 130/0.4in paediatric cardiac patients-a reply[J].Anaesthesia,2018,73(5):651-652.
[2]ORVIETO R,DRATVIMAN-STOROBINSKY O,COHEN Y.Interleukin-2 production by cultured human granulosa cells[J].Am J Reprod Immunol,2015,74(5):392-397.
[3]CHEN S U,CHOU C H,LIN C W,et al.Signal mechanisms of vascular endothelial growth factor and interleukin-8in ovarian hyperstimulation syndrome:dopamine targets their common pathways[J].Hum Reprod,2010,25(3):757-767.
[4]ABRAMOV Y,NAPARSTEK Y,ELCHALAL U,et al.Plasma immunoglobulins in patients with severe ovarian hyperstimulation syndrome[J].Fertil Steril,1999,71(1):102-105.
[5]DELVIGNE A,ROZENBERG S.Review of clinical course and treatment of ovarian hyperstimulation syndrome(OHSS)[J].Hum Reprod Update,2003,9(1):77-96.
[6]LEVIN I,GAMZU R,HASSON Y,et al.Increased erythrocyte aggregation in ovarian hyperstimulation syndrome:apossible contributing factor in the pathophysiology of this disease[J].Hum Reprod,2004,19(5):1076-1080.
[7]郭莉,张晓霞.羟乙基淀粉溶液对卵巢过度刺激综合征的预防作用[J].吉林大学学报(医学版),2016,42(6):1147-1150.
[8]倪亚莉,柴三明.羟乙基淀粉溶液预防卵巢过度刺激综合征的系统评价[J].实用妇产科杂志,2013,29(7):539-542.
[9]RIZK B.Symposium:Update on prediction and management of OHSS.Genetics of ovarian hyperstimulation syndrome[J].Reprod Biomed Online,2009,19(1):14-27.
[10]YOUSSEF M,AL-INANY H G,EVERS J L,et al.Intravenous fluids for the prevention of severe ovarian hyperstimulation syndrome[J].Cochrane Database Syst Rev,2011(2):CD001302.
[11]王佩玉,赵军招.中药和万汶在预防卵巢过度刺激综合征中的临床应用比较[J].温州医科大学学报,2017,47(2):104-109.
[12]KONIG E,BUSSEN S,SUTTERLIN M,et al.Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients:aprospective,randomized,double-blind and placebo-controlled study[J].Hum Reprod,1998,13(9):2421-2424.
[13]MATORRAS R,ANDRES M,MENDOZA R,et al.Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients:randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch[J].Eur J Obstet Gynecol Reprod Biol,2013,170(2):439-443.
[14]ABRAMOV Y,FATUM M,ABRAHAMOV D,et al.Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome:apreliminary report[J].Fertil Steril,2001,75(6):1228-1230.
[15]KIESEWETTER H,BLUME J,JUNG F,et al.Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb[J].J Intern Med,1990,227(2):107-114.
[16]YOUSSEF M A,MOURAD S.Volume expanders for the prevention of ovarian hyperstimulation syndrome[J].Coch Datab Syst Rev,2016(8):CD001302.
[17]GUO J L,ZHANG D D,ZHAO Y,et al.Pharmacologic interventions in preventing ovarian hyperstimulation syndrome:a systematic review and network meta-analysis[J].Sci Rep,2016,6:19093.
[18]MOURAD S,BROWN J,FARQUHAR C.Interventions for the prevention of OHSS in ART cycles:an overview of Cochrane reviews[J].Coch Datab Syst Rev,2017,1:CD012103.
[19]EL-KHAYAT W,ELSADEK M.Calcium infusion for the prevention of ovarian hyperstimulation syndrome:a double-blind randomized controlled trial[J].Fertil Steril,2015,103(1):101-105.
[20]NAREDI N,TALWAR P,SANDEEP K.VEGF antagonistforthepreventionofovarianhyperstimulation syndrome:Current status[J].Med J Armed Forces India,2014,70(1):58-63.
[21]JEE B C,SUH C S,KIM Y B,et al.Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome:a systematic review and meta-analysis[J].Gynecol Obstet Invest,2010,70(1):47-54.
[22]王兰,赵义清.卵巢过度刺激综合征临床相关研究进展[J].发育医学电子杂志,2015,3(2):116-120.
[23]TANG H,MOURAD S,ZHAI S D,et al.Dopamine agonists for preventing ovarian hyperstimulation syndrome[J].Coch Datab Syst Rev,2016,11:CD008605.
[24]JEE B C,SUH C S.Administration of intravenous albumin around the time of oocyte retrieval reduces preenancy rate without preventing ovarian hyper stimulation syndrome:a systematic review and meta-analysis[J].Gynecol Obstet Invest,2010,70(1):47-54.
[25]VENETIS C A,KOLIBIANAKIS E M.Intavenous albumin administration for the prevention of sever ovarian hyper stimulation syndrome:A systematic review and metaanalysis[J].Fertile Sterile,2011,95(1):162-164.
[26]赵玲玲,樊丽莎.多囊卵巢综合征的诊断学现状[J].中国实验诊断学,2015,19(1):162-164.
[27]LAXENAIRE M C,CHARPENTIER C,FELDMAN L.Anaphylactoid reactions to colloid plasma substitutes:incidence,risk factors,mechanisms.A French multicenter prospective study[J].Ann Fr Anesth Reanim,1994,13(3):301-310.
[28]BELLOMO R,BION J,FNFER S,et al.Open letter to the Executive Director of the European Medicines Agency concerning the licensing of hydroxyethyl starch solutions for fluid resuscitation[J].Br J Anaesth,2014,112(3):595-600.
[29]MARGRAF A,HERTER J M,KUEHNE K,et al.6%Hydroxyethyl starch(HES 130/0.4)diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice[J].Crit Care,2018,22(1):111.
[30]OH H W,LEE J H,KIM J T.Safety of hydroxyethyl starch 130/0.4in paediatric cardiac patients-a reply[J].Anaesthesia,2018,73(5):651-652.